NCT06997198View on ClinicalTrials.gov

Deutetrabenazine Treatment for Tardive Dyskinesia in Intellectual/Developmental Disabilities

PHASE4Not yet recruitingINTERVENTIONAL
Enrollment

25

Participants

Timeline

Start Date

November 1, 2025

Primary Completion Date

October 1, 2027

Study Completion Date

October 1, 2027

Conditions
Tardive DyskinesiaIntellectual DisabilityDevelopmental Disabilities
Interventions
DRUG

Deutetrabenazine Oral Capsule

Open-label twenty-four-week treatment with Deutetrabenazine oral tablets (up to 24 mg/day) to test the safety and effectiveness of this medication in ameliorating the signs of tardive dyskinesia in persons with intellectual disability.

Trial Locations (1)

44106

University Hospitals of Cleveland, Cleveland

All Listed Sponsors
collaborator

Teva Pharmaceuticals USA

INDUSTRY

lead

University Hospitals Cleveland Medical Center

OTHER